Stockscreener 앱 받기
87.18
0.18%
-0.16
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
(PTGX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Galesburg Register Mail
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - The Coloradoan
Protagonist Therapeutics Earnings Notes - Trefis
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Daytona Beach News-Journal
Aug Selloffs: Why Protagonist Therapeutics Inc stock is recommended by analystsJuly 2025 Pullbacks & Smart Allocation Stock Reports - moha.gov.vn
Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Chart Watch & Growth Focused Stock Reports - DonanımHaber
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trade Summary & Low Risk Investment Opportunities - DonanımHaber
Why Protagonist Therapeutics Inc. stock is favored by top institutionsPortfolio Risk Report & Fast Gain Stock Tips - DonanımHaber
How Protagonist Therapeutics Inc. stock benefits from strong dollar2025 Risk Factors & Real-Time Volume Spike Alerts - DonanımHaber
Is Protagonist Therapeutics Inc. stock a contrarian buyChart Signals & Consistent Income Trade Recommendations - Улправда
Why Protagonist Therapeutics Inc. stock is recommended by analysts2025 Volatility Report & Reliable Volume Spike Trade Alerts - Улправда
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6%Should You Sell? - MarketBeat
Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq
Protagonist Therapeutics (PTGX) Target Price Raised by Barclays - GuruFocus
How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results - Sahm
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Green Bay Press-Gazette
Three Stocks That May Be Undervalued In December 2025 - Sahm
Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - Sahm
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year HighWhat's Next? - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat
683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 93.53 USD By Investing.com - Investing.com Australia
Protagonist Therapeutics stock hits all-time high at 93.53 USD - Investing.com India
Citizens maintains Protagonist Therapeutics stock rating, citing rusfertide efficacy By Investing.com - Investing.com Canada
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
VIX Spike: How Protagonist Therapeutics Inc stock benefits from strong dollar2025 Winners & Losers & Fast Entry Momentum Trade Alerts - moha.gov.vn
How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
High Growth Tech Stocks In The US Market With Potential - Yahoo Finance
Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Comet
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)? - Sahm
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - STT Info
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Central New Jersey News
Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
0.57%
자본화:
|
볼륨(24시간):